{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:16:46Z","timestamp":1778692606515,"version":"3.51.4"},"reference-count":24,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi-Sankyo Europe","award":["N.A."],"award-info":[{"award-number":["N.A."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background and Objectives: Atrial fibrillation (AF) is associated with increased mortality, predictors of which are poorly characterized. We investigated the predictive power of the commonly used CHA2DS2-VASc score (congestive heart failure, hypertension, age \u2265 75 years [doubled], diabetes, stroke\/transient ischemic attack\/thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65\u201375 years, sex category [female]), the HAS-BLED score (hypertension, abnormal renal\/liver function, stroke, bleeding history or predisposition, labile international normalized ratio [INR], elderly [age \u2265 65 years], drugs\/alcohol concomitantly), and their combination for mortality in AF patients. Methods: The PREvention oF thromboembolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF) was a prospective registry including AF patients across seven European countries. We used logistic regression to analyze the relationship between the CHA2DS2-VASc and HAS-BLED scores and outcomes, including mortality, at one year. We evaluated the performance of logistic regression models by discrimination measures (C-index and DeLong test) and calibration measures (Hosmer and Lemeshow goodness-of-fit and integrated discrimination improvement (IDI), with bootstrap techniques for internal validation. Results: In 5209 AF patients with complete information on both scores, average one-year mortality was 3.1%. We found strong gradients between stroke\/systemic embolic events (SSE), major bleeding and\u2014specifically\u2014mortality for both CHA2DS2-VASc and HAS-BLED scores, with a similar C-statistic for event prediction. The predictive power of the models with both scores combined, removing overlapping components, was significantly enhanced (p &lt; 0.01) compared to models including either CHA2DS2-VASc or HAS-BLED alone: for mortality, C-statistic: 0.740, compared to 0.707 for CHA2DS2-VASc or 0.646 for HAS-BLED alone. IDI analyses supported the significant improvement for the combined score model compared to separate score models for all outcomes. Conclusions: Both the CHA2DS2-VASc and the HAS-BLED scores predict mortality similarly in patients with AF, and a combination of their components increases prediction significantly. Such combination may be useful for investigational and\u2014possibly\u2014also clinical purposes.<\/jats:p>","DOI":"10.3390\/jcm9123987","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T20:18:22Z","timestamp":1607631502000},"page":"3987","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Mortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation"],"prefix":"10.3390","volume":"9","author":[{"given":"Doralisa","family":"Morrone","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 50124 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Kroep","sequence":"additional","affiliation":[{"name":"Pharmerit\u2014An OPEN Health Company, 3068 AV Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1401-6623","authenticated-orcid":false,"given":"Fabrizio","family":"Ricci","sequence":"additional","affiliation":[{"name":"Institute of Cardiology and Center of Excellence on Aging, G. d\u2019Annunzio University, 66100 Chieti-Pescara, Italy"},{"name":"Fondazione VillaSerena per la Ricerca, Citt\u00e0 Sant\u2019Angelo, 65013 Pescara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Renda","sequence":"additional","affiliation":[{"name":"Institute of Cardiology and Center of Excellence on Aging, G. d\u2019Annunzio University, 66100 Chieti-Pescara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Diseases, University of Eastern Piedmont, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0197","authenticated-orcid":false,"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"University of Birmingham Institute of Cardiovascular Sciences, University of Birmingham, UHB and SWBH NHS Trusts, Birmingham B15 2TT, UK"},{"name":"Heart and Vascular Center, Hamburg University, 20251 Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Hsiang","family":"Chuang","sequence":"additional","affiliation":[{"name":"Pharmerit\u2014An OPEN Health Company, 3068 AV Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"van Hout","sequence":"additional","affiliation":[{"name":"Pharmerit\u2014An OPEN Health Company, 3068 AV Rotterdam, The Netherlands"},{"name":"School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield S10 2TN, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 50124 Pisa, Italy"},{"name":"Fondazione VillaSerena per la Ricerca, Citt\u00e0 Sant\u2019Angelo, 65013 Pescara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomstr\u00f6m-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., and Dilaveris, P.E. (2020). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J.","DOI":"10.1093\/eurheartj\/ehab648"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1177\/2047487319868320","article-title":"CHA2DS2VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation","volume":"26","author":"Renda","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11239-019-01860-7","article-title":"De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: A systematic review and meta-analysis","volume":"48","author":"Angiolillo","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jama.2015.10725","article-title":"Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation","volume":"314","author":"Melgaard","year":"2015","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijcard.2012.09.148","article-title":"Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: The Chin-Shan Community Cohort Study","volume":"168","author":"Lip","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11239-014-1154-6","article-title":"Association of the CHADS2 and CHA 2DS 2-VASc scores with left atrial enlargement: A prospective cohort study of unselected atrial fibrillation patients","volume":"40","author":"Dluzniewski","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: Primary results of the PREvention oF thromboemolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europaceschu"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: A framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1002\/sim.7286","article-title":"Event rate net reclassification index and the integrated discrimination improvement for studying incremental value of risk markers","volume":"36","author":"Moons","year":"2017","journal-title":"Stat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/ejcts\/ezaa071","article-title":"Assessing the performance of risk prediction models","volume":"58","author":"Nezic","year":"2020","journal-title":"Eur. J. Cardio-Thorac. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","article-title":"Probability of stroke: A risk profile from the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"ref_16","first-page":"332","article-title":"Newly Detected Atrial Fibrillation: AAFP Updates Guideline on Pharmacologic Management","volume":"96","author":"Hauk","year":"2017","journal-title":"Am. Fam. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1160\/TH13-07-0552","article-title":"Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial","volume":"110","author":"Apostolakis","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.amjcard.2017.07.051","article-title":"Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation","volume":"120","author":"Yao","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCEP.111.967000","article-title":"Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation","volume":"5","author":"Gallego","year":"2012","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jjcc.2016.02.005","article-title":"Predictive performance of HAS-BLED risk score for long-term survival in patients with non-ST elevated myocardial infarction without atrial fibrillation","volume":"69","author":"Hsieh","year":"2017","journal-title":"J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1076029615627341","article-title":"Higher CHA2DS2-VASc score is associated with increased mortality in acute pulmonary embolism","volume":"23","author":"Onuk","year":"2017","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/europace\/eut190","article-title":"CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy","volume":"16","author":"Bartolini","year":"2014","journal-title":"Europace"},{"key":"ref_23","first-page":"429","article-title":"The association between CHA2DS2-VASc score and mortality in patients with heart failure with reduced ejection fraction","volume":"33","author":"Temizer","year":"2017","journal-title":"Acta Cardiol. Sin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e017157","DOI":"10.1136\/bmjopen-2017-017157","article-title":"Improved risk stratification of patients with atrial fibrillation: An integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation","volume":"7","author":"Fox","year":"2017","journal-title":"BMJ Open"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/12\/3987\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:42:51Z","timestamp":1760179371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/12\/3987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jcm9123987"],"URL":"https:\/\/doi.org\/10.3390\/jcm9123987","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]}}}